Sam Penza
Overview
Explore the profile of Sam Penza including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
375
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Sharma N, Zhao Q, Ni B, Elder P, Puto M, Benson D, et al.
Cancers (Basel)
. 2021 Feb;
13(4).
PMID: 33557088
Acute graft versus host disease (aGVHD) remains a leading cause of morbidity and mortality in allogeneic hematopoietic stem cell transplant (allo-HSCT). Tacrolimus (TAC), a calcineurin inhibitor that prevents T-cell activation,...
12.
Rasor B, Dickerson T, Zhao Q, Elder P, Brammer J, Larkin K, et al.
Leuk Lymphoma
. 2020 Nov;
62(4):944-951.
PMID: 33231122
A retrospective cohort study was conducted to assess differences in efficacy and tolerability between a busulfan AUC target of 16.4 mg × Hr/L per day (FluBu4K) and a conventional RIC...
13.
Grana A, Gut N, Williams K, Maakaron J, Porter K, William B, et al.
Clin Lymphoma Myeloma Leuk
. 2020 Nov;
21(4):238-245.
PMID: 33132101
Background: Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma. Recent advances in immunotherapy have resulted in the development of chimeric antigen receptor-modified T-cell (CAR-T) therapy, such...
14.
Kittai A, Bond D, William B, Saad A, Penza S, Efebera Y, et al.
Blood Adv
. 2020 Oct;
4(19):4648-4652.
PMID: 33002129
No abstract available.
15.
Maakaron J, Liscynesky C, Boghdadly Z, Huang Y, Agyeman A, Brammer J, et al.
Biol Blood Marrow Transplant
. 2020 Apr;
26(8):e198-e201.
PMID: 32304873
Prophylaxis with fluoroquinolone (FQ) for patients undergoing autologous stem cell transplantation (ASCT) remains controversial. We performed a retrospective review of patients undergoing ASCT with and without bacterial prophylaxis to compare...
16.
Issa H, Sharma N, Zhao Q, Ruppert A, Elder P, Benson D, et al.
Biol Blood Marrow Transplant
. 2019 Jun;
25(10):1993-2001.
PMID: 31229641
The appropriate dose of antithymocyte globulin (ATG) to be used in reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (allo-HSCT) is yet to be determined. We retrospectively analyzed the outcomes...
17.
Singer S, Sharma N, Dean R, Zhao Q, Abounader D, Elder P, et al.
Bone Marrow Transplant
. 2019 Feb;
54(10):1553-1561.
PMID: 30718797
High-dose chemotherapy followed by autologous hematopoietic cell transplantation (AHCT) is an effective salvage therapy for patients with relapsed chemosensitive non-Hodgkin's lymphoma (NHL). However, the optimal conditioning regimen is unclear. Different...
18.
Singer S, Dean R, Zhao Q, Sharma N, Abounader D, Elder P, et al.
Biol Blood Marrow Transplant
. 2019 Feb;
25(6):1107-1115.
PMID: 30716453
High-dose chemotherapy followed by autologous hematopoietic stem cell transplant (AHSCT) is a standard of care for patients with relapsed Hodgkin lymphoma. Different conditioning regimens before AHSCT have been used, with...
19.
Vaughn J, Zhao Q, Epperla N, Puto M, Roddy J, Elder P, et al.
Bone Marrow Transplant
. 2018 Nov;
54(6):913-916.
PMID: 30413812
No abstract available.
20.
Wall S, Zhao Q, Yearsley M, Blower L, Agyeman A, Ranganathan P, et al.
Blood Adv
. 2018 Oct;
2(20):2619-2628.
PMID: 30327370
Transplant-associated thrombotic microangiopathy (TA-TMA), a complication of hematopoietic cell transplant (HCT), is associated with significant morbidity and mortality. The pathophysiology and overlap of TA-TMA with other posttransplant complications such as...